Zimmer Biomet Holdings (ZBH)’s 2026 Expectations Remain Cautious Amid Internal Reset

Core Insights - Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has presented cautious expectations for 2026, indicating significant internal changes are planned [2] - The company revised its 2025 organic revenue growth forecast down to 4.00% from 4.50% due to weaker demand in Latin America and emerging European markets, although overall revenue growth estimates remained stable due to favorable currency impacts [2] - Management cited last-minute cancellations of distributor orders from the Middle East and Eastern Europe as a key factor affecting performance [2] Company Ratings and Price Targets - Bernstein raised its price target for Zimmer Biomet Holdings from $97.00 to $99.00 while maintaining a 'Market Perform' rating, noting improved clarity in macro and policy uncertainties for U.S. healthcare stocks [2] - JPMorgan maintained a 'Neutral' rating on the company with a $100 price target, viewing 2026 as a pivotal year with growth opportunities while fundamentals remain strong [2] Business Focus - Zimmer Biomet Holdings specializes in designing, manufacturing, and marketing orthopedic, spine, dental, and surgical products globally [2]